

### **REMARKS**

Claims 1-60 are pending in the present application, where claims 11-32, 41-51, and 53-60 have been withdrawn from consideration. By this amendment, claims 11-32, 41-51, and 53-60 have been cancelled, claims 1-4, 7-10, 31-40, and 52 have been amended, and claims 61-75 have been added. Accordingly, claims 1-10, 33-40, 52, and 61-75 are currently under consideration. Applicant respectfully submits that these claims are allowable.

No new matter has been added. Support for new claims can be found in the original specification. Claims 61, 63, and 74 relate to a “computer” (e.g., page 12 at par. 16). Claims 62, 64, and 75 relate to “least-squares” (e.g, page 23 at par. 42). Claims 65-73 relate to claims 2-10.

### **Claim Rejections Under 35 USC § 101**

Claims 1-10, 33-40, and 52 stand rejected under 35 USC § 101 for failing to provide a tangible result. The claims have been amended to include limitations for “*saving at least one value based on the virtual patient’s FPG at time t.*” In this way, the claimed invention produces a tangible result as in the saved “*at least one value based on the virtual patient’s FPG at time t.*”

Applicant respectfully requests that the above-cited rejection under 35 USC § 101 be withdrawn.

### **Claim Rejections Under 35 USC § 112 (second paragraph)**

Claims 3-10 and 33-40 stand rejected under 35 U.S.C § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the Applicant regards as the invention. Applicant respectfully submits that the claims as amended satisfy the requirements of 35 U.S.C § 112, second paragraph.

Appropriate amendments have been made to clarify the language of the claims. In particular, claim 3 been amended to include “*the parameters a, b, c, and d are set to reflect a*

*population that is represented by the virtual patient.” Claim 3 has been amended to include “ $DF_2$  is a type 2 diabetes feature that represents an incidence of type 2 diabetes for the virtual patient.” Claim 10 has been amended to include “wherein  $DF_1$  is a type 1 diabetes feature that represents an incidence of type 1 diabetes for the virtual patient,  $DF_2$  is a type 2 diabetes feature that represents an incidence of type 2 diabetes for the virtual patient,  $H$  represents a degree of insulin resistance in a person with diabetes, and the parameters  $a$  and  $b$  are set to reflect a population that is represented by the virtual patient.” Other amendments have also been made to clarify the language of the claims as requested by the Examiner.*

Applicant respectfully requests that the above-cited rejection under 35 U.S.C § 112, second paragraph, be withdrawn.

### **Corrections for Informalities**

Additionally, certain claims have been amended to improve formal structure and not to overcome a rejection based on cited references. Claims 1, 3, 7, 31, 33, 37, and 52 have been amended to remove the unnecessary word “*differential*.” Claims 2 and 32 have been amended to avoid ambiguity related to the specification of the inequality. Claim 35 has been amended to remove the unnecessary word “*Women*” (e.g., as in claim 5). Claim 36 has been amended to clarify the proper claim dependency.

**CONCLUSION**

In view of the above, each of the presently pending claims in this application is believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to withdraw the outstanding rejection of the claims and to pass this application to issue. If it is determined that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number given below.

In the event the U.S. Patent and Trademark office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. **14-1437** referencing docket no. **8223.002.CPUS02**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: June 4, 2007

Respectfully submitted,

By           /Robert E. Scheid/  
Robert E. Scheid  
Registration No.: 42,126

NOVAK DRUCE & QUIGG LLP  
525 Market Street, Suite 3750  
San Francisco, CA 94105  
Phone: 415-814-6170  
Facsimile: 415-814-6165